Skip to main content

Ono Pharmaceutical

Ono Pharmaceutical Co Ltd is a Japanese R&D-oriented biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapies in oncology, immunology, and neurology. The company's premier commercial product is Opdivo, a human anti-PD-1 monoclonal antibody used globally as an immune checkpoint inhibitor for oncology treatments. Its product pipeline covers novel monoclonal antibodies, small molecule targeted drugs, and therapeutic agents for metabolic disorders and central nervous system diseases. Principal revenue is generated from direct commercial sales of prescription pharmaceuticals in Japan, alongside international licensing royalties and milestone payments from biopharmaceutical partner Bristol Myers Squibb. Ono Pharmaceutical is one of Japan's leading biopharmaceutical companies, recognized for pioneering cancer immunotherapy research. Headquartered in Osaka, Japan, the company's common stock is publicly listed and traded on the Prime Market of the Tokyo Stock Exchange under the ticker 4528.

10 of the funds FundTelligence covers report a position in Ono Pharmaceutical.

Legal name
Ono Pharmaceutical Co Ltd
Sector
Health Care
Country
Japan
Funds holding it
10

Funds holding Ono Pharmaceutical

Showing the 8 largest of 10 funds holding it.

Loading...